20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • Directory of Abstract Indexing for Journals
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences
Journal Flyer
Flyer image
WRN helicase inhibition and induced mitotic catastrophe for selective cancer therapy
6th International Conference and Exhibition on Cell and Gene Therapy
March 27-28, 2017 Madrid, Spain

Nayef Jarrous, Natalie Orlovetskie and Raphael Serruya

The Hebrew University - Hadassah Medical School, Israel

Scientific Tracks Abstracts: J Stem Cell Res Ther


WRN helicase has multiple roles in genome maintenance, such as replication, excision repair, DNA damage response and transcription. These processes are often found upregulated in human cancers, many of which display increased levels of WRN. Therefore, directed inhibition of this helicase, which belongs to a family of conserved RecQ helicases, could be beneficial to selective cancer therapy. Targeted inhibition of WRN is feasible by the use of the EGS/RNase P system in cultured human cell lines. Remarkably, EGS-directed WRN depletion leads to a marked decrease in cell viability due to mitotic catastrophe, associated with cessation of cell proliferation and replication induced by DNA repair failure and fork progression arrest. Moreover, we present new evidence that helicase depletion results in early changes of RNA polymerase III and RNase P activities, thus implicating two chromatin-bound tRNA enzymes in WRN-related stress response. Together with recent discovery of new roles of RecQ helicases in cancer, present data back the prospect of targeting of these genome guardians in cancers, in an attempt to develop clinical phases meant to diminish adaptive resistance to present-day targeted therapies.

Biography :

Nayef Jarrous is currently working at The Hebrew University of Jerusalem, Israel. His research interest is based on Human nuclear RNase P ribonucleoprotein in tRNA processing. He has published many articles in reputed journals.

Email: jarrous@md.huji.ac.il